TOP HEADLINES

SPECIAL REPORT

New discount persuades NICE to bless J&J's Zytiga

Britain's cost-effectiveness watchdog reversed its decision against the Johnson & Johnson prostate cancer pill, thanks to the company's new discount offer.

ASCO data to shine new light on Pfizer, Roche, J&J drugs

Cancer drug aficionados, rejoice. A slew of new studies goes public later today, as drugmakers gear up for next month's American Society of Clinical Oncology meeting.

Pennsylvania still trying get a slice of J&J Risperdal payouts

PA alleges that J&J oversold the drug's benefits while underselling the risks.

NIH taps Genentech drug for pioneering Alzheimer's study

Researchers will test crenezumab in Colombians with a particular genetic mutation, aiming to see if the drug can stop Alzheimer's before it starts.

Ex-BMS exec finishes book, and sentence, in conviction

A former Bristol-Myers Squibb executive has completed his sentence with a book on the Plavix scandal.

MORE NEWS

From Our Sister Sites

FierceBiotechIT

Knode has sprung to life with web-based software to enable life sciences stakeholders to hunt for top experts.

FierceBiotech

The deal comes amid rapid business expansion at Decision Resources, which provides web-based research tools, predictive analytics and other services to drugmakers and other healthcare stakeholders.